神经炎症
小胶质细胞
脑病
医学
药理学
白藜芦醇
活性氧
生物相容性材料
神经科学
慢性创伤性脑病
中枢神经系统
血脑屏障
缺氧缺血性脑病
炎症
癌症研究
谷氨酸受体
脑损伤
化学
氧化应激
缺氧(环境)
药品
兴奋毒性
细胞凋亡
作者
Chanyue Wang,Kangqian Tian,Changfeng Jia,Liguo Song,Caifan Wang,Weipeng Gao,Zhaojuan Wang,Jiacan Xu,Yuchen Li,Yalin Li,Qian Liu
摘要
Hypoxic-ischemic encephalopathy (HIE) is a major cause of neurological injury in neonates, with pathological cascades such as neuroinflammation and ferroptosis driving disease progression. Current therapeutic strategies for HIE are largely limited to supportive care and therapeutic hypothermia, which fail to effectively target these mechanisms. To address this challenge, we developed a microglia-derived exosome-liposome hybrid membrane systems (HMS) (R+si@LPs-TK/TAT+Exo, abbreviated as Rs@LP-T/T-E) for the co-delivery of resveratrol (RES) and acyl-CoA synthetase long-chain family member 4 (ACSL4) siRNA. The nanosystem exhibited favorable stability, reactive oxygen species (ROS)-responsive drug release, and efficient blood-brain barrier (BBB) penetration, enabling targeted accumulation within ischemic brain regions. In experimental models, Rs@LP-T/T-E significantly attenuated neuroinflammation and ferroptosis, promoted microglial polarization toward the anti-inflammatory M2 microglial phenotype, and restored mitochondrial function, thereby reducing cerebral infarct volume and improving cerebral perfusion. In conclusion, this study presents an efficient, targeted, and biocompatible nanodelivery strategy that holds strong translational potential for HIE therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI